@article {Sun:2020:0736-8046:970,
title = "Treatment of MEK inhibitorinduced paronychia with doxycycline",
journal = "Pediatric Dermatology",
parent_itemid = "infobike://bsc/pde",
publishercode ="bp",
year = "2020",
volume = "37",
number = "5",
publication date ="2020-09-01T00:00:00",
pages = "970-971",
itemtype = "ARTICLE",
issn = "0736-8046",
eissn = "1525-1470",
url = "https://www.ingentaconnect.com/content/bsc/pde/2020/00000037/00000005/art00058",
doi = "doi:10.1111/pde.14276",
keyword = "MEK inhibitor, neurofibromatosis, NF1, selumetinib, paronychia, doxycycline",
author = "Sun, Qisi and Antaya, Richard J.",
abstract = "A 12yearold girl with neurofibromatosis type 1 and a large facial plexiform neurofibroma had been participating in a selumetinib clinical trial for the past 5years. Despite decreased tumor size, she developed recalcitrant selumetinibinduced paronychia.
Various antibiotics, topical medications, and surgeries were only minimally effective. Fulldose doxycycline resolved the paronychia, and subantimicrobial dosing has prevented recurrences for several months, permitting her to continue her selumetinib course.",
}